Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 4
2017 2
2018 4
2019 2
2020 4
2021 4
2022 1
2023 4
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.
Roussos Torres ET, Ho WJ, Danilova L, Tandurella JA, Leatherman J, Rafie C, Wang C, Brufsky A, LoRusso P, Chung V, Yuan Y, Downs M, O'Connor A, Shin SM, Hernandez A, Engle EL, Piekarz R, Streicher H, Talebi Z, Rudek MA, Zhu Q, Anders RA, Cimino-Mathews A, Fertig EJ, Jaffee EM, Stearns V, Connolly RM. Roussos Torres ET, et al. Nat Cancer. 2024 Jun;5(6):866-879. doi: 10.1038/s43018-024-00729-w. Epub 2024 Feb 14. Nat Cancer. 2024. PMID: 38355777 Clinical Trial.
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma.
Fanucci K, Pilat MJ, Shyr D, Shyr Y, Boerner S, Li J, Durecki D, Drappatz J, Puduvalli V, Lieberman FS, Gonzalez J, Giglio P, Ivy SP, Bindra RS, Omuro A, LoRusso P. Fanucci K, et al. Cancer Res Commun. 2023 Feb 2;3(2):192-201. doi: 10.1158/2767-9764.CRC-22-0436. eCollection 2023 Feb. Cancer Res Commun. 2023. PMID: 36968138 Free PMC article. Clinical Trial.
Normalization Cancer Immunotherapy for Melanoma.
Vesely MD, Chen L. Vesely MD, et al. J Invest Dermatol. 2020 Jun;140(6):1134-1142. doi: 10.1016/j.jid.2020.02.005. Epub 2020 Feb 22. J Invest Dermatol. 2020. PMID: 32092349 Free PMC article.
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J. Cecchini M, et al. Br J Cancer. 2024 Feb;130(3):476-482. doi: 10.1038/s41416-023-02534-1. Epub 2023 Dec 22. Br J Cancer. 2024. PMID: 38135713 Free PMC article. Clinical Trial.
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. Maldonado E, et al. Cancer Res Commun. 2024 Jul 1;4(7):1793-1801. doi: 10.1158/2767-9764.CRC-24-0213. Cancer Res Commun. 2024. PMID: 38920407 Free PMC article. Clinical Trial.
Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.
Hendricks WPD, Zismann V, Sivaprakasam K, Legendre C, Poorman K, Tembe W, Perdigones N, Kiefer J, Liang W, DeLuca V, Stark M, Ruhe A, Froman R, Duesbery NS, Washington M, Aldrich J, Neff MW, Huentelman MJ, Hayward N, Brown K, Thamm D, Post G, Khanna C, Davis B, Breen M, Sekulic A, Trent JM. Hendricks WPD, et al. PLoS Genet. 2018 Sep 6;14(9):e1007589. doi: 10.1371/journal.pgen.1007589. eCollection 2018 Sep. PLoS Genet. 2018. PMID: 30188888 Free PMC article.
24 results